A Zephyr valve is a tiny one-way valve implanted inside the airways to treat severe emphysema. It works by blocking air from entering the most damaged parts of the lung while letting trapped air and fluid escape, which shrinks the diseased section and gives the healthier parts of the lung more room to expand and function. The FDA approved it in 2018, and it remains the only endobronchial valve cleared for use in the United States.
How the Valve Works
In emphysema, damaged air sacs lose their elasticity and trap stale air. Over time, these overinflated regions crowd out the healthier tissue around them, making it progressively harder to breathe. This is called lung hyperinflation, and it’s the core problem the Zephyr valve targets.
The device itself is small, roughly the size of a pencil eraser. It consists of a silicone duckbill valve mounted on a self-expanding metal frame made of nitinol, a nickel-titanium alloy. When placed inside an airway leading to a damaged lobe, the valve allows air to vent out during exhalation but prevents fresh air from refilling that region during inhalation. Over time, the trapped air escapes through the valve, the diseased lobe deflates, and the surrounding healthy lung tissue can expand into the freed-up space. The result is improved airflow and less breathlessness.
Who Is a Candidate
Zephyr valves are intended for adults with severe emphysema who haven’t responded well to standard treatments like bronchodilators, corticosteroids, or anti-inflammatory medications, and who aren’t good candidates for lung volume reduction surgery or lung transplant. The valves fill a gap for people whose disease is too advanced for medication alone but who can’t safely undergo a major operation.
One critical requirement is the absence of collateral ventilation in the targeted lobe. Collateral ventilation refers to small air passages that connect neighboring sections of the lung. In emphysema, the breakdown of lung tissue often opens up these side channels. If air can sneak into the treated lobe through collateral pathways, the valve can’t do its job because the lobe simply refills from a different direction. To check for this, doctors use a tool called the Chartis system during a bronchoscopy. A balloon catheter is placed at the entrance of the target lobe to seal it off, and sensors measure whether airflow gradually stops (meaning no collateral ventilation, good news) or continues for more than five minutes (meaning collateral ventilation is present, and valves won’t work). This single test is often the deciding factor in whether someone can proceed.
Several conditions rule out the procedure entirely:
- Active lung infection
- Current smoking or not having quit
- Large bullae (air-filled spaces) taking up more than 30% of either lung
- Allergy to nitinol, nickel, titanium, or silicone
- Inability to tolerate bronchoscopy
What the Procedure Looks Like
The valves are placed during a bronchoscopy, a procedure where a thin, flexible scope is guided through the mouth or nose and into the airways. You’re typically under general anesthesia. The doctor identifies the airways leading to the most damaged lobe and deploys multiple valves to seal off that section completely. The entire procedure takes 30 to 60 minutes.
Afterward, you’ll stay in the hospital for three to five days. This observation period exists largely because of the risk of pneumothorax, a condition where air leaks out of the lung and into the chest cavity. The first few days are when this risk is highest, and doctors want to catch it quickly if it happens. Recovery at home is relatively fast compared to surgery since there are no incisions, but breathing improvements may take days to weeks as the treated lobe gradually deflates.
How Well It Works
The primary measure of lung function improvement is FEV1, which reflects how much air you can forcefully exhale in one second. At one year after valve placement, patients in clinical studies showed an average FEV1 improvement of about 17% from their baseline. Nearly half of patients (49.6%) achieved an improvement of 15% or greater, a threshold considered clinically meaningful. For someone with severe emphysema who has been steadily losing lung function, that kind of gain can translate into noticeably easier breathing, more capacity for physical activity, and better quality of life.
The valves are also removable. If they shift position, cause problems, or if a patient’s condition changes, a doctor can retrieve them during another bronchoscopy. This reversibility is one of the key advantages over surgical options like lung volume reduction, which permanently removes tissue.
Risks and Complications
Pneumothorax is the most significant risk. In a study of 532 patients, 19% experienced a pneumothorax following valve implantation. Other published data report rates as high as 34%. The risk window extends through the first three months after the procedure, though most cases occur in the first few days, which is why the hospital stay is built in. A pneumothorax can range from minor (resolving on its own with monitoring) to serious (requiring a chest tube to drain the trapped air).
Other possible complications include a flare-up of COPD symptoms, coughing, and, less commonly, valve migration where a valve shifts out of position. Infections in the treated lobe can also occur. Most complications are manageable, but the pneumothorax rate in particular is something to weigh carefully when deciding whether the procedure is right for you.
Insurance Coverage
Coverage for Zephyr valves varies and can be complicated to navigate. Medicare does not have a national coverage determination for endobronchial valves, meaning there’s no blanket federal policy guaranteeing payment. Coverage decisions are made regionally or on a case-by-case basis. Private insurers typically require documentation that the patient meets specific criteria: severe emphysema with hyperinflation, confirmed absence of collateral ventilation, failure of conventional medical therapy, and unsuitability for lung surgery. Getting prior authorization often involves detailed pulmonary function testing and imaging to demonstrate medical necessity.